share_log

Avinger Announces Conversion of $11 Million of CRG Debt Into Preferred Equity

Avinger Announces Conversion of $11 Million of CRG Debt Into Preferred Equity

Avinger宣佈將1,100萬美元的CRG債務轉換爲優先股
Accesswire ·  05/17 04:05

REDWOOD CITY, CA / ACCESSWIRE / May 16, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today announced the conversion of $11 million or approximately 80% of its existing debt with entities affiliated with CRG Partners III L.P. ("CRG") into a shares of a new series of convertible preferred stock.

加利福尼亞州雷德伍德城/ACCESSWIRE/2024年5月16日/Avinger, Inc.(納斯達克股票代碼:AVGR)是一家處於商業階段的醫療器械公司,該公司開發和銷售第一款也是唯一一款用於血管疾病診斷和治療的血管內影像引導、基於導管的系統,今天宣佈將其與CRG Partners III L.P.(“CRG”)關聯實體的1,100萬美元(約佔其現有債務的80%)轉換爲CRG Partners III L.P.(“CRG”)關聯實體的1,100萬美元,約佔其現有債務的80% 新系列可轉換優先股的股票。

Following the conversion, the outstanding principal amount of debt with CRG is $2.6 million. The debt conversion results in an $11 million increase in stockholders' equity.

轉換後,CRG的未償債務本金爲260萬美元。債務轉換導致股東權益增加1100萬美元。

Complete details of the conversion are available in an 8-K filed with the U.S. Securities and Exchange Commission today.

轉換的完整詳細信息可在今天向美國證券交易委員會提交的8-K中查閱。

"We appreciate CRG's continued support as we expand our proprietary image-guided technology to new markets and advance the development of our innovative coronary artery disease platform," said Jeff Soinski, Avinger's President and CEO. "Converting the majority of our outstanding debt to equity strengthens our balance sheet and supports Avinger's efforts to regain compliance with the Nasdaq's stockholder equity standard for continued listing."

Avinger總裁兼首席執行官傑夫·索因斯基表示:“我們感謝CRG在我們將專有的圖像引導技術擴展到新市場並推進創新型冠狀動脈疾病平台開發方面給予的持續支持。”“將我們的大部分未償債務轉換爲股權可以增強我們的資產負債表,並支持Avinger努力恢復遵守納斯達克股東權益標準以繼續上市。”

About Avinger, Inc.

關於 Avinger, Inc.

Avinger is a commercial-stage medical device company that designs and develops the first image-guided, catheter-based system for the diagnosis and treatment of patients with vascular disease in the peripheral and coronary arteries. Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox series of imaging consoles, the Ocelot and Tigereye family of chronic total occlusion (CTO) catheters, and the Pantheris family of atherectomy devices for the treatment of peripheral artery disease (PAD), estimated to affect more than 200 million people worldwide. Avinger is developing its first product application for the treatment of coronary artery disease (CAD), an image-guided system for CTO-crossing in the coronary arteries, which provides the opportunity to redefine a large and underserved market. Avinger is based in Redwood City, California. For more information, please visit .

Avinger 是一家處於商業階段的醫療器械公司,設計和開發了第一款基於圖像引導的導管系統,用於診斷和治療外周動脈和冠狀動脈血管疾病患者。Avinger致力於通過其Lumibasular平台從根本上改變血管疾病的治療方式,該平台目前包括Lightbox系列成像控制檯、Ocelot和Tigereye系列慢性全閉塞(CTO)導管以及用於治療外周動脈疾病(PAD)的Pantheris系列動脈切除術,估計影響全球超過2億人。Avinger正在開發其首款用於治療冠狀動脈疾病(CAD)的產品應用程序,這是一種用於冠狀動脈CTO穿刺的圖像引導系統,它爲重新定義龐大且服務不足的市場提供了機會。Avinger 總部位於加利福尼亞州雷德伍德城。欲了解更多信息,請訪問。

Follow Avinger on Twitter and Facebook.

在推特和臉書上關注 Avinger。

Forward-Looking Statements

前瞻性陳述

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding regaining compliance with the Nasdaq's stockholder equity standard. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include our dependency on a limited number of products; the resource requirements related to Pantheris, Tigereye and our Lightbox imaging console; the outcome of clinical trial results; the adoption of our products by physicians; our ability to obtain regulatory approvals for our products; as well as the other risks described in the section entitled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2024, and Quarterly Reports on Form 10-Q. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Avinger disclaims any obligation to update these forward- looking statements.

本新聞稿包含1933年《證券法》第27A條、1934年《證券交易法》第21E條和1995年《私人證券訴訟改革法》所指的前瞻性陳述。這些前瞻性陳述包括有關恢復遵守納斯達克股東權益標準的陳述。此類陳述基於當前的假設,這些假設涉及風險和不確定性,可能導致實際結果和結果出現重大差異。這些風險和不確定性,其中許多是我們無法控制的,包括我們對有限數量產品的依賴;與Pantheris、Tigereye和我們的Lightbox成像控制檯相關的資源需求;臨床試驗結果的結果;醫生對我們產品的採用;我們的產品獲得監管部門批准的能力;以及標題爲 “風險因素” 的部分和我們提交的10-K表年度報告其他地方描述的其他風險 2024 年 3 月 20 日與美國證券交易委員會會面,每季度一次表格 10-Q 上的報告。這些前瞻性陳述僅代表截至本文發佈之日,不應過分依賴這些前瞻性陳述。Avinger不承擔任何更新這些前瞻性陳述的義務。

Investor Contact:
Matt Kreps
Darrow Associates Investor Relations
(214) 597-8200
mkreps@darrowir.com

投資者聯繫人:
馬特·克雷普斯
達羅聯合投資者關係
(214) 597-8200
mkreps@darrowir.com

Public Relations Contact:
Phil Preuss
Chief Marketing Officer
Avinger, Inc.
(650) 241-7942
pr@avinger.com

公共關係聯繫人:
菲爾·普魯斯
首席營銷官
Avinger, Inc.
(650) 241-7942
pr@avinger.com

SOURCE: Avinger, Inc.

來源:Avinger, Inc.


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論